tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Corbus Pharmaceuticals price target lowered to $53 from $70 at Jefferies

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to $1.2B from $1.7B, the analyst noted. The CRB-913 obesity study will dose its first patient by the end of March and Corbus is likely to share data from the dose-ranging study in the first half of 2026, Jefferies added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1